These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 25858666)

  • 1. Recent advances on anti-HIV vaginal delivery systems development.
    Antimisiaris SG; Mourtas S
    Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
    Woodsong C; Holt JD
    Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-based nanocarriers for vaginal drug delivery.
    das Neves J; Nunes R; Machado A; Sarmento B
    Adv Drug Deliv Rev; 2015 Sep; 92():53-70. PubMed ID: 25550217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Special issue on vaginal drug delivery.
    de Oliveira RP; de Oliveira JM; Caramella C
    Adv Drug Deliv Rev; 2015 Sep; 92():1. PubMed ID: 26452325
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaginal drug distribution modeling.
    Katz DF; Yuan A; Gao Y
    Adv Drug Deliv Rev; 2015 Sep; 92():2-13. PubMed ID: 25933938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucoadhesive and thermogelling systems for vaginal drug delivery.
    Caramella CM; Rossi S; Ferrari F; Bonferoni MC; Sandri G
    Adv Drug Deliv Rev; 2015 Sep; 92():39-52. PubMed ID: 25683694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for local treatment of vaginal infections.
    Palmeira-de-Oliveira R; Palmeira-de-Oliveira A; Martinez-de-Oliveira J
    Adv Drug Deliv Rev; 2015 Sep; 92():105-22. PubMed ID: 26144995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal microbicides: moving ahead after an unexpected setback.
    van de Wijgert JH; Shattock RJ
    AIDS; 2007 Nov; 21(18):2369-76. PubMed ID: 18025873
    [No Abstract]   [Full Text] [Related]  

  • 10. The future of HIV microbicides: challenges and opportunities.
    Garg AB; Nuttall J; Romano J
    Antivir Chem Chemother; 2009; 19(4):143-50. PubMed ID: 19374141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.
    Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J
    Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
    Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future microbicide approaches aimed at preventing HIV infection in women.
    Pozzetto B; Delézay O; Brunon-Gagneux A; Hamzeh-Cognasse H; Lucht F; Bourlet T
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):167-83. PubMed ID: 22339191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific microbicides in the prevention of HIV infection.
    Kelly CG; Shattock RJ
    J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-based vaginal drug delivery systems for HIV prevention.
    Mallipeddi R; Rohan LC
    Expert Opin Drug Deliv; 2010 Jan; 7(1):37-48. PubMed ID: 20017659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessments of vaginal microbicide candidate safety and efficacy.
    Fernández-Romero JA; Teleshova N; Zydowsky TM; Robbiani M
    Adv Drug Deliv Rev; 2015 Sep; 92():27-38. PubMed ID: 25543007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.
    Braunstein S; van de Wijgert J
    J Womens Health (Larchmt); 2005 Jun; 14(5):424-33. PubMed ID: 15989415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of HIV neutralization by a microbicide formulation layer: biophysical fundamentals and transport theory.
    Geonnotti AR; Katz DF
    Biophys J; 2006 Sep; 91(6):2121-30. PubMed ID: 16815899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrospun fibers for vaginal anti-HIV drug delivery.
    Blakney AK; Ball C; Krogstad EA; Woodrow KA
    Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges.
    Nunes R; Sarmento B; das Neves J
    J Control Release; 2014 Nov; 194():278-94. PubMed ID: 25229988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.